Clinical

A study from Sweden, the largest of its kind, challenges the standard 24-month milestone as the key point when early relapse is a concern.

Real-world ONCare data show acalabrutinib lowers new-onset HTN, CV events, and discontinuations vs ibrutinib in R/R CLL/SLL.

In a pair of lively debates at the International Stroke Conference 2026, experts from around the world discussed controversies in stroke care.

Susan Vadaparampil, PhD, MPH, highlights disparities in cancer outcomes and trial enrollment but underscores that linking community screening programs with cancer centers may help.

Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL measures into trials is urgently needed.

Targeted therapies, bispecifics, and CAR T-cell therapies are giving patients with multiple myeloma hope for long-term remission or a potential cure.

A deep-learning serial CT response score outperformed conventional imaging measures in predicting OS for patients with advanced NSCLC treated with ICIs.

City St. George’s researchers identified 9 genetic signatures and epigenetic changes driving lapatinib resistance in HER2-positive breast cancer.

Ateequllah Hayat, PhD, discusses epigenetic rewiring, biomarkers, and emerging strategies to overcome lapatinib resistance in HER2+ breast cancer.

Real-world inotuzumab ozogamicin boosts remission in relapsed/refractory B-cell ALL, supports transplant, and flags sinusoidal obstruction syndrome risk.

Experts discuss the challenges of integrating new cancer therapies, addressing multidisciplinary care, evolving guidelines, and the financial burden on patients.

Experts discuss the promising future of HER2-targeted therapies, highlighting new treatments and combination strategies for non-small cell lung cancer.

Experts discuss the potential of TKIs like zongertinib and seviberatinib as first-line treatments for HER2-mutant non-small cell lung cancer.

Nurse navigators play a crucial role in managing HER2-targeted therapy side effects, ensuring patient education and early toxicity detection.

Telomere length and polygenic risk independently influence IPF susceptibility, even among patients without rare genetic variants.

Maui Derm 2026 showcased groundbreaking advancements in dermatology, focusing on biologics, innovative treatments, and future technologies for skin health.

Explore the safety considerations and unique toxicities of bispecific antibodies, including cytokine release syndrome and neurotoxicity management.

Explore the latest advancements in bispecific antibodies for multiple myeloma, focusing on early treatment opportunities and innovative trial designs.

Glaucoma is a leading cause of blindness in the US, making awareness of the condition vital to obtaining the best outcomes.

Patients with mantle cell lymphoma experience improved quality of life and physical functioning after treatment with pirtobrutinib, a BTK inhibitor.

These findings suggest the mental health burden in nonmelanoma skin cancer reflects broader social and clinical factors rather than disease-specific effects.

Tildrakizumab at 100-mg and 200-mg doses showed long-term effectiveness for managing psoriasis in challenging areas in a real-world study.

Discover how innovations in biology and engineering are transforming dermatology, featuring breakthroughs in laser therapies and precision medicine.

Experts discuss the signs and symptoms, treatment methods, and the future of glaucoma as Glaucoma Awareness Month concludes.